RIBOZYME AND OMICS

PIPELINE

Summary

Development Stage

Product Candidate Target Indication Discovery Pre-clinical Phase1 Phase2 Phase3
RZ-001
Hepatocellular carcinoma Phase1

RZ-001

  • Stage : Phase I
  • Indication : Hepatocellular carcinoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-001_immune therapy combination
Hepatocellular carcinoma Phase1

RZ-001_immune therapy combination

  • Stage : Phase I
  • Indication : Hepatocellular carcinoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection (Adenovirus) / Intravenous (Immune checkpoint inhibitor)

    • Partnership

RZ-001 (GBM)
Glioblastoma Phase1

RZ-001 (GBM)

  • Stage : Phase I
  • Indication : Glioblastoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-002
Glioblastoma Pre-clinical

RZ-002

  • Stage : Pre-clinical
  • Indication : Glioblastoma
  • Target : Telomerase reverse transcriptase (TERT)
  • Delivery Vehicle : Adenovirus
  • Dose Route : Intra-tumoral injection
RZ-003
Alzheimer Discovery

RZ-003

  • Stage : Discovery
  • Indication : Alzheimer
  • Target : Apolipoprotein E (APOE4)
  • Delivery Vehicle : Adeno-associated virus (AAV)
  • Dose Route : Intra-cisternal injection
RZ-004
Retinitis Pigmentosa Pre-clinical

RZ-004

  • Stage : Pre-clinical
  • Indication : Retinitis Pigmentosa
  • Target : Mutant Rhodopsin
  • Delivery Vehicle : Adeno-associated virus (AAV)
  • Dose Route : Sub-retinal injection
New platform
- Discovery

New platform

  • New platform
  • Stage : Discovery

Expanded Access Policy

Expanded Access Program

Expanded access is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Rznomics Inc. is developing RZ-001, a gene therapy for patients with Hepatocellular Carcinoma (HCC) and Glioblastoma (GBM). Our primary focus is on enrolling patients in our ongoing clinical trials which are necessary to gain regulatory approvals and to make our therapies available to patients as quickly as possible. Therefore, participation in one of our clinical trials is the best way to access our investigational products. Further information about our clinical trials can be found by searching ‘Rznomics’ on ClinicalTrials.gov.




About EAP for Glioblastoma (GBM)

At this time, expanded access is primarily considered for GBM. If enrollment in a clinical trial is not possible or feasible, expanded access offers a possible route for gaining access to an investigational product. Rznomics will consider requests for expanded access on a case-by-case basis. If you are a patient wishing to access Rznomics investigational products, please discuss this with your treating doctor. For more information, please contact us at Rznomics@rznomics.com.